Here you find Investor News of year 2002.
Ad-hoc messages issued in year 2002 can be found here.
Publications of the previous years are offered in the Archive Overview.
To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.
Receive our IR news via E-Mail, RSS Feed or SMS.
December 20, 2002 | Bayer reaches agreement with U.S. authorities
|
December 16, 2002 | FDA Approves Once-Daily Cipro® XR for the Treatment of Uncomplicated Urinary Tract Infections (UTIs)U
|
December 6, 2002 | Plans for the future of Pharmaceuticals have the support of the Supervisory Board
|
December 5, 2002 | Strategic options for Rhein Chemie under review
|
December 5, 2002 | New rules for Corporate Governance
|
December 2, 2002 | Bayer and GlaxoSmithKline: Two New Studies on Erectile Dysfunction Presented
|
November 29, 2002 | Acarbose - Findings of the first large-scale study
|
November 22, 2002 | Vardenafil Receives Positive Opinion from European Committee for Proprietary Medicinal Products
|
November 13, 2002 | Bayer CropScience to sell additional products to Makhteshim-Agan
|
November 12, 2002 | Q3 2002 Statement
|
November 11, 2002 | Bayer sells household insecticides for EUR 725 million to SC Johnson
|
October 30, 2002 | Bayer Submits Additional New Drug Application For Once-Daily Cipro XR in U.S.
|
October 28, 2002 | Rolf Classon Appointed Chairman of the Board of Management of Bayer HealthCare AG
|
October 28, 2002 | Bayer CropScience AG to sell a range of products to BASF
|
October 28, 2002 | Bayer's Cipro Patent Affirmed by U.S. Courts
|
October 16, 2002 | Bayer and SC Johnson have signed Letter of Intent
|
October 4, 2002 | Bayer plans to sell Rhein Chemie to Advent International
|
October 2, 2002 | Bayer CropScience agrees to products divestments to Makhteshim-AganBayer
|
October 1, 2002 | Approval of 200 liter fermenters for Kogenate increases production capacity for the U.S.
|
October 1, 2002 | Bayer CropScience becomes first legally independent subgroup
|
October 1, 2002 | Study Comparing Once-Daily Cipro XR to Conventional Twice-Daily Cipro
|
September 23, 2002 | ISSIR Congress: New Vardenafil Data
|
September 18, 2002 | Bayer CropScience agrees to sell wheat herbicide to Arvesta Corporation
|
September 12, 2002 | Bayer cuts a further 4,700 jobs worldwide
|
August 27, 2002 | New Immune Globulin Intravenous Treatment for Approval in Key Global Markets Submitted
|
August 15, 2002 | Pharmaceuticals Division signs declaration of intent to market telmisartan
|
August 01, 2002 | Stockholder's Newsletter 2002: Interim Report for the First Half
|
July 24, 2002 | Bayer agrees to acquire Visible Genetics Inc. for US$ 61.4 million
|
July 24, 2002 | FDA approvable letter for Vardenafil
|
July 17, 2002 | Bayer plans to sell Haarmann & Reimer to EQT
|
June 03, 2002 | Bayer CropScience ready for launch
|
May 31, 2002 | Bayer to keep fibers business
|
May 31, 2002 | FTC gives the green light for Bayer to acquire Aventis CropScience
|
May 30, 2002 | Bayer sells stake in Agfa-Gevaert
|
May 22, 2002 | Bayer taking additional steps to realign cost base of Pharmaceutical Business
|
May 21, 2002 | New BAY 43-9006 Phase I data presented at 2002 ASCO meeting
|
May 13, 2002 | New EUR 170 million TDA plant
|
May 02, 2002 | Avalox i.v. approved in Germany: noticeable drop in treatment costs possible
|
April 26, 2002 | Information for Stockholders 2002: Interim Report for the First Quarter
|
April 25, 2002 | Moxifloxacin IV Reduces Healthcare Costs and Provides Excellent Outcome for Patients hospitalized with Community-Acquired Pneumonia
|
April 17, 2002 | Bayer divests generics business in Spain
|
April 17, 2002 | European Commission clears planned transaction:Bayer can acquire Aventis CropScience
|
April 15, 2002 | New Bayer management team now complete
|
April 04, 2002 | Bayer Pharma France sells generics business to Teva
|
March 25, 2002 | Bayer's euro bonds a resounding success
|
March 13, 2002 | Bayer expects much higher net income in 2002
|
March 12, 2002 | Bayer plans to divest household insecticides
|
March 08, 2002 | Bayer Corporation Submits New Drug Application for Once-Daily Formulation of Ciprofloxacin HCI and Ciprofloxacin
|
March 07, 2002 | Klaus Kühn and Dr. Richard Pott appointed to the Bayer Management Board
|
March 07, 2002 | Bayer to pay dividend of EUR 0.90 per share
|
March 06, 2002 | Active ingredient in Aspirin reduces the risk of myocardial infarction and stroke
|
February 26, 2002 | Patients Reported Vardenafil Significantly Improved Erectile Function Following Radical Prostatectomy
|
February 20, 2002 | Bayer and Aventis Sign Letter of Intent on Joint Venture of Blood Plasma Business
|
February 05, 2002 | Bayer receives offer for generics business in France
|
January 31, 2002 | Bayer and GlaxoSmithKline Announce: EMEA Acceptance of Regulatory Filing for Vardenafil
|
January 24, 2002 | Bayer stock makes its debut on the New York Stock Exchange
|
January 22, 2002 | "New" Bayer Group will be more flexible to boost competitiveness and performance
|
January 11, 2002 | Syngenta and Bayer reach agreement on patent disputes
|
January 09, 2002 | Dr. Wolfgang Plischke appointed new General Manager of the Pharmaceuticals Business Group
|
January 09, 2002 | Bayer and Burrill & Company form diagnostics capital fund
|
collect